MAM
CYT

Meeder Asset Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Meeder Asset Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3
Closed – – 2424
2022
Q2 		$0 Hold
3
– – ﹤0.01% 2492
2022
Q1 		$0 Buy
+3
New +$17 ﹤0.01% 2569

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meeder Asset Management's CYT Position: Q3 2022 in Review

Meeder Asset Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2022, closing a stake of 3 shares.

Meeder Asset Management first reported a position in CYT in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 37 funds tracked by Wall St. Rank hold CYT as of Q3 2022.

  • Meeder Asset Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Meeder Asset Management sold 3 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Meeder Asset Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Meeder Asset Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Meeder Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.